| Title |
Laquinimod for multiple sclerosis.
|
|---|---|
| Published in |
Cochrane database of systematic reviews, August 2013
|
| DOI | 10.1002/14651858.cd010475.pub2 |
| Pubmed ID | |
| Authors |
He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S, He, Dian, Han, Kai, Gao, Xiangdong, Dong, Shuai, Chu, Lan, Feng, ZhanHui, Wu, Shan, Dian He, Kai Han, Xiangdong Gao, Shuai Dong, Lan Chu, ZhanHui Feng, Shan Wu |
| Abstract |
Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegenerative disorder of the central nervous system, and it causes major socioeconomic burden for the individual patient and for society. An inflammatory pathology occurs during the early relapsing stage of MS and a neurodegenerative pathology dominates the later progressive stage of the disease. Not all MS patients respond adequately to currently available disease-modifying drugs (DMDs). Alternative MS treatments with new modes of action are required to expand the current options for disease-modifying therapies (DMTs) and to aim for freedom from relapses, inflammatory lesions, disability progression and neurodegeneration. Laquinimod has dual properties of immunomodulation and neuroprotection and is a potentially promising new oral DMD in the treatment of relapsing MS. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 40% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
| Scientists | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 130 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| South Africa | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 127 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 23 | 18% |
| Student > Ph. D. Student | 15 | 12% |
| Researcher | 13 | 10% |
| Student > Bachelor | 12 | 9% |
| Other | 7 | 5% |
| Other | 21 | 16% |
| Unknown | 39 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 50 | 38% |
| Nursing and Health Professions | 12 | 9% |
| Psychology | 7 | 5% |
| Social Sciences | 4 | 3% |
| Biochemistry, Genetics and Molecular Biology | 3 | 2% |
| Other | 8 | 6% |
| Unknown | 46 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 November 2022.
All research outputs
#1,981,489
of 23,172,045 outputs
Outputs from Cochrane database of systematic reviews
#4,342
of 12,383 outputs
Outputs of similar age
#17,741
of 198,549 outputs
Outputs of similar age from Cochrane database of systematic reviews
#91
of 243 outputs
Altmetric has tracked 23,172,045 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,383 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 32.5. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 198,549 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 243 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.